Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376.57M | $312.97M | $245.11M | $203.56M | $132.33M | $90.10M | $54.38M | $25.43M |
| Cost of Revenue | $185.57M | $179.63M | $155.38M | $119.33M | $80.62M | $61.41M | $47.43M | $32.19M |
| Gross Profit | $191.00M | $133.35M | $89.73M | $84.23M | $51.71M | $28.69M | $6.96M | $-6.76M |
| Gross Margin | 50.72% | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% |
| Operating Expenses | $327.26M | $354.18M | $306.89M | $319.01M | $204.44M | $168.77M | $115.81M | $63.80M |
| Operating Income | $-136.26M | $-220.83M | $-217.16M | $-234.78M | $-152.73M | $-140.08M | $-108.85M | $-70.56M |
| Operating Margin | -36.18% | -70.56% | -88.60% | -115.33% | -115.41% | -155.47% | -200.15% | -277.50% |
| Net Income | $-77.67M | $-208.73M | $-204.62M | $-217.86M | $-152.10M | $-139.93M | $-107.67M | $-71.24M |
| Net Margin | -20.63% | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% |
| EPS (Basic) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 | $-2.68 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |